


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9 (canceled)

Claim 10 (new): A polymorph of the compound of formula A:



which is Form I.

Claim 11 (new): The polymorph in accordance with Claim 10 wherein the polymorph has an x-ray powder diffraction pattern peak position, Cu K alpha, at about 9.7 degrees 2-theta.

Claim 12 (new): The polymorph in accordance with Claim 11 wherein the polymorph has at least one additional x-ray powder diffraction pattern peak position, Cu K alpha, at about 7.1, 11.8, 15.5 20.1, 22.7 and 24.1 degrees 2-theta.

Claim 13 (new): A pharmaceutical composition comprised of a Form I polymorph of Compound A in accordance with claim 10 in combination with a pharmaceutically acceptable carrier.

Claim 14 (new): The pharmaceutical composition in accordance with Claim 13 wherein the Form I polymorph has the physical characteristics described in the following table:

Form	I
XRPD (peak positions, Cu K alpha)	7.1
	9.7
	11.8
	15.5
	20.1
	22.7
	24.1